Plasma concentrations of nitric oxide and asymmetric dimethylarginine in human alcoholic cirrhosis.
about
Asymmetric dimethylarginine blocks nitric oxide-mediated alcohol-stimulated cilia beatingAsymmetric dimethylarginine as a mediator of vascular dysfunction in cirrhosisManagement options in decompensated cirrhosisEndothelial dysfunction in cirrhosis: Role of inflammation and oxidative stressRelationship between lean body mass and serum renal biomarkers in healthy dogsCurrent concepts in the diagnosis and classification of renal dysfunction in cirrhosis.Changes in ADMA/DDAH pathway after hepatic ischemia/reperfusion injury in rats: the role of bileHepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension.L-arginine and asymmetric dimethylarginine are early predictors for survival in septic patients with acute liver failure.The nitric oxide prodrug, V-PYRRO/NO, mitigates arsenic-induced liver cell toxicity and apoptosis.ADMA metabolism and clearance.Estimation of Glomerular Filtration Rate in Patients With Cirrhosis by Using New and Conventional Filtration Markers and Dimethylarginines.Asymmetric dimethylarginine is strongly associated with cognitive dysfunction and brain MR spectroscopic abnormalities in cirrhosis.Elevated nitric oxide and 3',5' cyclic guanosine monophosphate levels in patients with alcoholic cirrhosis.The prominent role of the liver in the elimination of asymmetric dimethylarginine (ADMA) and the consequences of impaired hepatic function.Transjugular intrahepatic portosystemic shunt-placement increases arginine/asymmetric dimethylarginine ratio in cirrhotic patientsIntracerebral Administration of S-Adenosylhomocysteine or S-Adenosylmethionine Attenuates the Increases in the Cortical Extracellular Levels of Dimethylarginines Without Affecting cGMP Level in Rats with Acute Liver Failure.Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL).Asymmetric Dimethylarginine and Hepatic Encephalopathy: Cause, Effect or Association?Toxic Dimethylarginines: Asymmetric Dimethylarginine (ADMA) and Symmetric Dimethylarginine (SDMA).Alcoholic liver disease: pathogenesis and new targets for therapy.The role of dimethylarginine dimethylaminohydrolase (DDAH) in pulmonary fibrosis.Increased circulatory asymmetric dimethylarginine and multiple organ failure: bile duct ligation in rat as a model.Management of hepatorenal syndrome.Effects of asymmetric dimethylarginine on renal arteries in portal hypertension and cirrhosis.Increased Plasma Levels of Asymmetric Dimethylarginine in Nonalcoholic Fatty Liver Disease: Relation With Insulin Resistance, Inflammation, and Liver Histology.Association of homoarginine and methylarginines with liver dysfunction and mortality in chronic liver disease.Caffeic Acid Phenethyl Ester inhibit Hepatic Fibrosis by Nitric Oxide Synthase and Cystathionine Gamma-Lyase in Rats.Noninvasive evaluation of portal hypertension: emerging tools and techniques.Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy.Liver plays a central role in asymmetric dimethylarginine-mediated organ injury.Modulation of arginine and asymmetric dimethylarginine concentrations in liver and plasma by exogenous hydrogen sulfide in LPS-induced endotoxemia.Conservation of whole body nitric oxide metabolism in human alcoholic liver disease: implications for nitric oxide production.Unchanged plasma levels of dimethylarginines and nitric oxide in chronic hepatitis C.Methylated arginines and nitric oxide in end-stage renal disease: impact of inflammation, oxidative stress and haemodialysis.Coronary vasospasm during the reversal of neuromuscular block using neostigmine.Accumulation of symmetric dimethylarginine in hepatorenal syndrome.Post-Transcriptional Regulation of Hepatic DDAH1 with TNF Blockade Leads to Improved eNOS Function and Reduced Portal Pressure In Cirrhotic Rats.New Developments in Hepatorenal Syndrome.Portal vein omentin is increased in patients with liver cirrhosis but is not associated with complications of portal hypertension.
P2860
Q23922132-0B288F5B-BF57-43B8-8B80-59C54001E519Q26795604-99EB4012-F13B-4D1F-A917-2FC72367F8B6Q26800238-E33229C7-0E72-4DC3-B755-218EA29492C4Q27023122-EF7C009B-F73A-4FFC-9293-A31CB93A9529Q28601638-60FC258A-0AC1-46D4-A393-97EA1430C373Q33811643-2D3603A7-7BA3-48AD-A758-023C0FF0F023Q34162190-0B3BB43C-C997-4AE2-B4A8-9DEB5DE94617Q35933350-901C3F63-854F-4162-96CA-871ED4EAA051Q35961528-C048C84F-B8F8-471D-AD8C-ECD4B76B5AC5Q36168425-313EA5B7-5D51-470E-8667-3F23639ACFDDQ36381017-1AD5874E-CF33-40FA-A128-5BC2032AC8CEQ36414936-EFD9C5D5-E9E8-48B5-B929-1F6A6CE90CC2Q36428010-2EEC2FD0-3187-4931-AEED-A09523B3A46DQ37174153-479E01E0-AD61-442C-8C46-AFFD92D6A216Q37313734-EDB11200-53C0-4A03-96FE-ECD9673275FBQ37420073-2B39A8C7-EFFD-4A39-B27F-AB16F23E0EF8Q37553510-DA509930-AB05-448B-B8CC-077EBA477252Q37577568-57D300CE-2FA1-473B-9FD3-7A5D1ED19EC6Q37710176-3AE4049C-B647-4A07-8B6B-8C60F1228E01Q37727924-4D273523-65E2-463E-9B92-80773230DC76Q37913987-E27B8BD3-441C-41FB-817E-578ACBA00714Q38055449-7601CB1E-2F5F-4C0A-9318-8EE1BAB04670Q38194032-19494C0B-1450-4F6D-A89B-30B6D6800C74Q38463841-76C9F911-74B0-497F-9BCF-4B959EBB9EA7Q40038186-80B73014-63B2-4AA1-88CC-10F5F4589BB3Q40658220-E5D76748-28E9-4CC7-BA45-650D175CD976Q41754942-8B44CC9F-2628-4791-A488-873B8A790BD6Q41840520-1B4F986E-3385-48F8-B627-08F6712FFB55Q42202921-378624C2-4A7B-4F1C-9548-BC13DEEEFD35Q42571705-BBF6EBEE-9749-474C-8093-CA1E5678C8A3Q42575439-8EBF3026-7133-407E-BE12-B2084AF38504Q43920852-D4B97162-4921-4A91-A190-342433060DB3Q44265366-FCD5DD45-3D53-41EC-A57D-91C96CFE8FAAQ46296923-0E05BEE2-0064-4AE0-8080-5C335B75DB47Q46343358-59FAC3CD-354A-4A33-9BE5-421C8EE87DD2Q46690489-379F7CCD-C7D4-4939-81D9-50788A9013C5Q46870364-64AE191C-4C8A-48F5-82D1-B7199388DDF4Q47134026-B4E5F117-CE51-4F63-AC7B-B09B838EF2ABQ47807120-F6B18B13-182C-49DC-A351-89E76EDA3F71Q48005805-99D2E6E2-1CC4-4E09-9C62-35DE6C812783
P2860
Plasma concentrations of nitric oxide and asymmetric dimethylarginine in human alcoholic cirrhosis.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Plasma concentrations of nitri ...... in human alcoholic cirrhosis.
@en
Plasma concentrations of nitri ...... in human alcoholic cirrhosis.
@nl
type
label
Plasma concentrations of nitri ...... in human alcoholic cirrhosis.
@en
Plasma concentrations of nitri ...... in human alcoholic cirrhosis.
@nl
prefLabel
Plasma concentrations of nitri ...... in human alcoholic cirrhosis.
@en
Plasma concentrations of nitri ...... in human alcoholic cirrhosis.
@nl
P2093
P1476
Plasma concentrations of nitri ...... in human alcoholic cirrhosis.
@en
P2093
Belén Torondel
Gloria Segarra
José M Rodrigo
Juan A Del Olmo
Miguel A Serra
Paloma Lluch
P356
10.1016/J.JHEP.2004.03.016
P577
2004-07-01T00:00:00Z